The Icon Group is an Australian healthcare company that focuses on providing multidisciplinary cancer care. It employs 1,700 people across the country and has a network of hospitals and clinics that are dedicated to this specialty. The group also provides climate-controlled, air-ride transportation to and from New York City, and conducts clinical trials and research. Moreover, it offers exclusive use vehicles for its patients. In addition, the company is also a leading provider of sterile pharmaceuticals.
The Icon Group is entering its next stage of global expansion after acquiring a minority stake in Integrated Clinical Oncology Network from EQT, a purpose-driven global investor. The company acquired the interests of a consortium of Goldman Sachs Asset Management, QIC and Pagoda Investment, and will re-invest the funds with Icon Group management. These investments will allow the company to further expand its reach globally.
The Icon Group is a global cancer-care operator. Its portfolio of services includes radiation and medical oncology. It also offers pharmacy and compounding services. Founded in New Zealand, the Icon Group has expanded its footprint across the Southern Hemisphere, building five regional and outer-metropolitan locations in Australia. With the recent investment, it hopes to grow its presence in Asia and the northern hemisphere.
In addition to investing in research and development, the Icon Theicongroup is developing new clinical sites globally. Its expansion plans have been significantly boosted by signing agreements with Siemens Healthineers and Varian Medical Systems. Those partnerships will help the company provide more advanced cancer care. The company plans to grow its network even further. It also wants to build a compounding facility. It is also aiming to improve its quality of life by improving the lives of its patients.
The Icon Group has been a successful company in the medical field since its launch in 2009. Its business has transacted over 1,000 titles and is now the largest private buyer of second-hand apartments in New Zealand. In 2012, it ranked thirteenth in the Deloitte Fast 50 awards. With the investment, the Icon Group is now able to expand its reach across the southern hemisphere and Asia. This is an excellent time for the Icon Group to build on its growth and reach more clients.
The Icon Group has established a network of clinical research hubs and comprehensive cancer centres. It also offers day-to-day oncology and radiation services. The Icon Group has shown great resilience in the COVID-19 period. Its investment plans have enabled the company to expand across APAC and northern hemisphere. It has also signed an agreement with Siemens Healthineers and Varian Medical Systems to conduct private clinical trials in the region.
The Icon Group is Australia’s largest private cancer care company, with its Icon Cancer Centre in Sydney. The group has expanded into Singapore, Mainland China, Hong Kong, and New Zealand. The company also has pharmacies in its various locations. These pharmacies provide pharmacy and medication management services to patients. With over two million cancer patients in Australia, the Icon Group is a leading private health care provider in the country. This innovative model is set to redefine the industry and provide high-quality cancer care to the nation’s communities.